Randomized double-blind clinical trial evaluating the effectiveness and safety of secondary prophylaxis with oral vancomycin versus placebo in the prevention of recurrence of <i>clostridioides difficile</i> infection in patients receiving systemic an
In high-risk patients with recent CDI requiring systemic antibiotics, SPV appeared safe and was associated with a clinically relevant reduction in recurrence, although the trial was underpowered. These findings support further adequately powered randomized studies to define the role of SPV in preventing CDI recurrence.
Authors
- Karen Campion
- JM Ferrari
- José Tiago Silva (ORCID: https://orcid.org/0000-0001-8765-3466)
- Julia Origüen (ORCID: https://orcid.org/0000-0002-6507-0363)
- Jorge Boán (ORCID: https://orcid.org/0000-0003-2682-0819)
- Beatriz Díaz-Pollán
- Giancarlo Candela
- J. M. Aguado
- María Asunción Pérez-Jacoiste Asín
- Cristina Martin-Arriscado
- Rafael San-Juan
- Eduardo Aparicio-Minguijón
- Isabel Rodríguez-Goncer
- Mario Fernández-Ruiz
- Francisco López-Medrano
- Alejandro Callejas-Díaz
- Jennifer VILLA
Institutions
- Universidad Complutense de Madrid (ES)
- Hospital Universitario La Paz (ES)
- Instituto de Salud Carlos III (ES)
- Research Institute Hospital 12 de Octubre (ES)
- Hospital Universitario 12 De Octubre (ES)
- Hospital La Paz Institute for Health Research (ES)
- Hospital Universitario Puerta de Hierro Majadahonda (ES)
- Spanish Clinical Research Network (ES)
- Centro de Investigación Biomédica en Red (ES)
- Hospital Clínico Universitario Lozano Blesa (ES)
- Hospital Universitario Severo Ochoa (ES)
Publication Details
- Journal
- JAC-Antimicrobial Resistance
- Published
- 2026-02-25
- DOI
- https://doi.org/10.1093/jacamr/dlag032
- Primary Topic
- Clostridium difficile and Clostridium perfringens research
- Type
- article
- Field-Weighted Citation Impact
- 0.00